Researchers at Radboud University Medical Center, Nijmegen, the Netherlands, have reported a novel approach to use exon skipping that may “patch” part of a gene… Read More »Therapeutic exon skipping strategies of Usher syndrome (USH2A) may provide mutation-independent approaches for treatment.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the June 18th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »June 18th, 2023 “EURETINA-Brief”© Issue No. 273
Astellas Pharma Inc. (TSE: 4503) and IVERIC Bio, Inc. (NASDAQ: ISEE) have announced a definitive agreement on May 1st under which Astellas has agreed to… Read More »Astellas Pharma Inc., (TSE: 4503) is to acquire Iveric Bio Inc., (NASDAQ: ISEE) for a purchase of US$5.9bn.
International clinical researchers at several collaborating institutes, from Pennsylvania to Istanbul, have reported results on the genetic contribution of the HLA-B/MICA genetic region to the… Read More »Genetic analysis in Behçet’s disease identifies novel loci associated with ocular and neurological involvement.
Researchers at the Institute of Basic Medical Sciences, University of Oslo, the Norwegian Association of the Blind and Partially Sighted, Oslo, and Roche Norway (F Hoffmann-La… Read More »Analysis reports the treatment burden of intravitreal anti-VEGF injections among a Norwegian cohort of patients and caregivers on nAMD.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the June 5th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »June 5th, 2023 “EURETINA-Brief”© Issue No. 272
A US company, LumiThera Inc., based in Seattle, WA has reported summary trial data on photo-biomodulation, termed “LIGHTSITE III” study, conducted by a multi-centre clinical… Read More »US “LIGHTSITE III” clinical trial data on photo-biomodulation (PBT) treatment of dry AMD has reported vision improvement for 24 months.
Researchers led by clinical scientists at the Department of Clinical Neurosciences, University of Oxford, UK, has reported that, previously, there have been no disease-specific instruments… Read More »Two new RP/LCA-specific instruments have reported strong evidence for psychometric validity on measures with RP/LCA adults and caregivers of children.
Researchers at ProQR Therapeutics, an RNA company based in Leiden, the Netherlands, and with researchers at Radboud University Medical Center in Nijmegen, have reported results… Read More »Antisense oligonucleotide (AON) therapy for Stargardt disease type 1 (STGD1) provides a proof of concept with effective restoration of correct ABCA4 transcript splicing.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the May 19th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »May 19th, 2023 “EURETINA-Brief”© Issue No. 271
